The current lifetime risk of prostate cancer for men living in Canada is estimated to be approximately one in eight, but incidence is highly dependent on the number of prostate-specific antigen (PSA)-driven biopsies [1,5–7]. The gene discussed is KLK3; the disease is prostate carcinoma.